These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6358418)

  • 21. Biologicals and biological response modifiers: design of clinical trials.
    Oldham RK
    J Biol Response Mod; 1985 Apr; 4(2):117-28. PubMed ID: 3889226
    [No Abstract]   [Full Text] [Related]  

  • 22. New drug development in the changing health care environment: a panel discussion.
    Flanagan A; Temple RJ; Wardell WM
    Ann N Y Acad Sci; 1981; 368():203-11. PubMed ID: 6942776
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract]   [Full Text] [Related]  

  • 24. Two ideas to increase innovation and reduce pharmaceutical costs and prices.
    Jayadev A; Stiglitz J
    Health Aff (Millwood); 2009; 28(1):w165-8. PubMed ID: 19088104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug regulation 2056.
    Bezold C; Peck J
    Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 27. Changing requirements for evaluation of pharmacologic agents.
    Chesney RW; Christensen ML
    Pediatrics; 2004 Apr; 113(4 Suppl):1128-32. PubMed ID: 15060209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How do we assure the quality of biological medicines?
    Longstaff C; Whitton CM; Stebbings R; Gray E
    Drug Discov Today; 2009 Jan; 14(1-2):50-5. PubMed ID: 18951998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are the drug-regulatory agencies paper villains?
    Smith T
    Br Med J; 1980 Nov; 281(6251):1333-5. PubMed ID: 7002251
    [No Abstract]   [Full Text] [Related]  

  • 30. Adopting orphan drugs: Congress tries to encourage new remedies for rare diseases.
    Wallis C
    Time; 1982 Oct; 120(15):76, 79. PubMed ID: 10317248
    [No Abstract]   [Full Text] [Related]  

  • 31. The learned intermediary doctrine: past, present and future.
    Alsobrook HB
    Leg Med; 1994; ():269-80. PubMed ID: 7830482
    [No Abstract]   [Full Text] [Related]  

  • 32. Democrats on drugs.
    Lancet; 2007 Jan; 369(9556):79. PubMed ID: 17223448
    [No Abstract]   [Full Text] [Related]  

  • 33. Natural products to drugs: natural product-derived compounds in clinical trials.
    Butler MS
    Nat Prod Rep; 2008 Jun; 25(3):475-516. PubMed ID: 18497896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 35. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
    Peck CC; Rubin DB; Sheiner LB
    Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
    [No Abstract]   [Full Text] [Related]  

  • 36. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 38. The challenge of integrating monoclonal antibodies into the current healthcare system.
    Brixner DI; Bull SA
    Am J Manag Care; 1997 Jun; 3(6):903-11. PubMed ID: 10170294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 40. Do natural compounds need specific drug development?
    Simon P; Verry M
    Prog Clin Biol Res; 1988; 280():407-21. PubMed ID: 3051029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.